Cost-Effectiveness Analysis of 68Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma.
暂无分享,去创建一个
S. Pannullo | J. Knisely | P. Sanelli | R. Magge | J. Ivanidze | S. Mahase | S. Kim | T. H. Schwartz | E. Lin | G. Martinez | M. Roytman | A. Haghdel | R. Ramakrishna | P.C. Sanelli | P. Pan | J. Rodriguez | G. Madera | J. R. Osborne | T. Schwartz | J.R. Osborne
[1] J. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2022, Neuro-oncology.
[2] C.-C. Jay Kuo,et al. Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018 , 2022, Journal of Neuro-Oncology.
[3] M. Mehta,et al. 68Ga-DOTATATE PET: The Future of Meningioma Treatment. , 2022, International journal of radiation oncology, biology, physics.
[4] M. Berger,et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities , 2022, Nature Genetics.
[5] T. Schwartz,et al. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma , 2021, Scientific Reports.
[6] Mark W. Youngblood,et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses , 2021, Research square.
[7] David C. Jones,et al. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Lydia Y. Liu,et al. A clinically applicable integrative molecular classification of meningiomas , 2021, Nature.
[9] Wengen Chen,et al. 68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas , 2021, Radiation Oncology.
[10] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[11] M. Weller,et al. EANO guideline on the diagnosis and management of meningiomas. , 2021, Neuro-oncology.
[12] C. Auernhammer,et al. Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors , 2021, Diagnostics.
[13] T. Schwartz,et al. Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center , 2021, Neuro-oncology advances.
[14] S. Nehmeh,et al. Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas , 2020 .
[15] D. Ramanathan,et al. Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management , 2020, Frontiers in Oncology.
[16] P. Stieg,et al. [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas , 2020, Neuro-oncology advances.
[17] E. Arias,et al. United States Life Tables, 2018. , 2020, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[18] J. Knisely,et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. , 2020, Clinical imaging.
[19] M. McDermott,et al. Surgical outcomes after reoperation for recurrent non-skull base meningiomas. , 2019, Journal of neurosurgery.
[20] T. Schwartz,et al. Gallium‐68 DOTATATE PET in the Evaluation of Intracranial Meningiomas , 2019, Journal of Neuroimaging.
[21] M. McDermott,et al. Surgical outcomes after reoperation for recurrent skull base meningiomas. , 2019, Journal of neurosurgery.
[22] N. Albert,et al. Recurrence pattern analysis after [68Ga]-DOTATATE-PET/CT -planned radiotherapy of high-grade meningiomas , 2018, Radiation oncology.
[23] M. Reiser,et al. Cost-effectiveness of Endovascular Therapy for Acute Ischemic Stroke: A Systematic Review of the Impact of Patient Age. , 2018, Radiology.
[24] D. Owens,et al. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma , 2017, Neuro-oncology.
[25] A. Laxton,et al. Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control , 2017, Journal of Clinical Neuroscience.
[26] M. Reiser,et al. Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET/CT Compared with Contrast-Enhanced MRI , 2017, The Journal of Nuclear Medicine.
[27] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[28] A. Buck,et al. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? , 2016, Neuro-oncology.
[29] Rory K. J. Murphy,et al. Radiation Therapy for Residual or Recurrent Atypical Meningioma: The Effects of Modality, Timing, and Tumor Pathology on Long-Term Outcomes. , 2016, Neurosurgery.
[30] D. Brachman,et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. , 2015, Journal of neurosurgery.
[31] M. Svensson,et al. The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature. , 2015, Health economics.
[32] C. Leães,et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. , 2015, International journal of clinical and experimental pathology.
[33] N. Samani,et al. QALYs in cost-effectiveness analysis: an overview for cardiologists , 2015, Heart.
[34] R. Hicks,et al. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.
[35] M. Roethke,et al. Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. , 2015, Neuro-oncology.
[36] Melissa A. Z. Knoll,et al. Incentivizing Delayed Claiming of Social Security Retirement Benefits Before Reaching the Full Retirement Age , 2014 .
[37] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[38] Joseph A Hill. United States Life Tables , 2013 .
[39] M. Wallander,et al. Epidemiology of Meningioma in the United Kingdom , 2012, Neuroepidemiology.
[40] Y. Garces,et al. Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas , 2012, Cancer.
[41] I. Steffen,et al. Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy - a case series , 2012, Head & Face Medicine.
[42] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[43] S. J. Whitehead,et al. Health outcomes in economic evaluation: the QALY and utilities. , 2010, British medical bulletin.
[44] S. Bae,et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.
[45] H. Fernandes,et al. Meningioma recurrence: The efficacy and cost-effectiveness of current screening , 2010, British journal of neurosurgery.
[46] W. Curry,et al. LONG‐TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION , 2009, Neurosurgery.
[47] D. Cohen,et al. Interpreting the results of cost-effectiveness studies. , 2008, Journal of the American College of Cardiology.
[48] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[49] Mark Payne,et al. Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.
[50] P. Wen,et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review , 2014 .
[51] R. Buchert,et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[52] Henry Brem,et al. Central nervous system cancers: Clinical Practice Guidelines in Oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.
[53] R. Martuza,et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. , 1985, Journal of neurosurgery.